1. Neumann PJ, Russell LB, Siegel JE, Prosser LA, Krahn M, Mandelblatt JS, et al. Using cost-effectiveness in health and medicine: experiences since the original panel. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors., et al., Cost-effectiveness in health and medicine. New York: Oxford University Press; 2017. p. 1–38.
2. Shi CR, Nambudiri VE. Research techniques made simple: cost-effectiveness analysis. J Investig Dermatol. 2017;137(7):e143–7. https://doi.org/10.1016/j.jid.2017.03.004.
3. Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509–22. https://doi.org/10.1007/s40273-017-0606-1.
4. Zhang W, Sun H, Woodcock S, Anis AH. Valuing productivity loss due to absenteeism: firm-level evidence from a Canadian linked employer-employee survey. Health Econ Rev. 2017;7(1):3. https://doi.org/10.1186/s13561-016-0138-y.
5. International Society for Pharmacoeconomics and Outcomes Research I, (ISPOR). Pharmacoeconomic guidelines around the world. International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA. 2020. https://www.tools.ispor.org/peguidelines/. Accessed 29 Mar 2020.